Research
Pyridoxine
61 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Pyridoxine Prevents Postoperative Nausea and Vomiting in Gynecologic Laparoscopic Surgery: A Double-blind Randomized Controlled Trial.
Double-blind RCT of 240 patients undergoing gynecologic laparoscopic surgery comparing pyridoxine to placebo for preventing postoperative nausea and vomiting. Pyridoxine significantly reduced the incidence of postoperative nausea and vomiting compared to the control group.
Genotype and phenotype features and prognostic factors of neonatal-onset pyridoxine-dependent epilepsy: A systematic review.
Systematic review of 56 studies involving 169 patients with neonatal-onset pyridoxine-dependent epilepsy. Pyridoxine treatment was associated with being seizure-free in 63.9% of patients, though 68.6% had neurodevelopmental delays. Early pyridoxine use was protective against developmental and language delays.
Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials.
This systematic review evaluates the efficacy and safety of Pyridoxine compared to dopaminergic agonists (cabergoline and bromocriptine) for post-partum lactation inhibition. The review found that dopaminergic agents were significantly more effective in inhibiting lactation compared to Pyridoxine.
The effects of pyridoxine (vitamin B6) supplementation in nausea and vomiting during pregnancy: a systematic review and meta-analysis.
Systematic review and meta-analysis evaluating pyridoxine (Vitamin B6) supplementation for nausea and vomiting during pregnancy. The analysis included 18 studies, showing that pyridoxine alone or in combination with other substances significantly improved symptoms according to Rhode's and PUQE scores.
Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures.
The ILAE Task Force on Neonatal Seizures developed evidence-based recommendations for antiseizure medication management in neonates. Phenobarbital is recommended as the first-line ASM, with phenytoin or carbamazepine for channelopathy-related seizures. Pyridoxine may be tried in cases of vitamin B6-dependent epilepsy unresponsive to second-line ASM.
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Meta-analysis of 16 RCTs with 2814 participants evaluating prophylactic strategies for hand-foot syndrome/skin reaction in cancer patients. Urea cream and celecoxib were effective in reducing risk, with celecoxib particularly effective for capecitabine-induced HFS and urea cream for sorafenib-induced HFSR. Pyridoxine showed a trend towards benefit but lacked sufficient evidence for recommendation.
A review of treatment modalities in gyrate atrophy of the choroid and retina (GACR).
Systematic review of 33 studies on therapeutic interventions for gyrate atrophy of the choroid and retina (GACR), involving 107 patients. Treatments included protein-restricted diets, pyridoxine, creatine, l-lysine, and proline supplementation. Protein-restricted diets and lysine supplementation were effective in lowering ornithine levels, while pyridoxine responsiveness was mutation-dependent.
Targeted Therapy- and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of interventions for cancer treatment-related skin toxicities. Prophylactic minocycline reduced acneform rash in erlotinib patients. Pyridoxine 400 mg lowered the risk of hand-foot syndrome in capecitabine-treated patients. Scalp cooling reduced severe hair loss from chemotherapy.
Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
Meta-analysis of 14 studies involving 1570 patients to evaluate the efficacy of pyridoxine (vitamin B6) in preventing hand-foot syndrome (HFS) caused by chemotherapy agents. The analysis found no significant differences between pyridoxine and control groups in preventing HFS or severe HFS, though there might be a tendency for pyridoxine to reduce HFS incidence.
Effect of Combined Diclofenac and B Vitamins (Thiamine, Pyridoxine, and Cyanocobalamin) for Low Back Pain Management: Systematic Review and Meta-analysis.
Systematic review and meta-analysis of randomized clinical trials assessing the effect of combining diclofenac with B vitamins (thiamine, pyridoxine, and cyanocobalamin) for low back pain management. The combination therapy showed a significant reduction in treatment duration compared to diclofenac monotherapy, with no differences in safety profile and patient satisfaction.
Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency.
Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. The guidelines re-evaluate and update previous recommendations for diagnosis, treatment, and follow-up, including the use of pharmacologic doses of pyridoxine and lysine-reduction therapies.
Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review.
Systematic review of studies on pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events (NPAEs) in epilepsy patients. Retrospective studies reported improvement in NPAEs in 72.5% of patients, while a prospective trial showed more relief in patients receiving pyridoxine. However, evidence quality is poor, and better-designed studies are needed.
Is pyridoxine effective and safe for post-partum lactation inhibition? A systematic review.
Systematic review evaluating the effectiveness and safety of high-dose pyridoxine for post-partum lactation inhibition. Seven studies with a total of 1155 women were included, with conflicting results on pyridoxine's efficacy. Two trials indicated effectiveness in inhibiting lactation, while others did not. No serious side effects were reported, but evidence remains inconsistent and insufficient.
Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.
Systematic review and meta-analysis of 5 RCTs involving 607 patients to assess pyridoxine (vitamin B6) for prevention of hand-foot syndrome (HFS) caused by chemotherapy. No significant differences were found between pyridoxine and placebo for prevention of HFS incidence or quality of life, though pyridoxine 400 mg daily showed some efficacy in preventing grade 2 or worse HFS compared to 200 mg.
Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events in pediatric and adolescent epilepsy: a prospective, double-blind, randomized, placebo-controlled trial.
This prospective, double-blind, randomized, placebo-controlled trial evaluated pyridoxine supplementation for reducing levetiracetam-related neuropsychiatric adverse events in children and adolescents with epilepsy. Both pyridoxine and placebo groups showed significant behavioral improvement over 8 weeks, but multivariate analysis revealed significantly greater improvement in the pyridoxine group. No serious adverse events occurred.
The efficiency of cabergoline vs pyridoxine for lactation inhibition-a randomized controlled trial.
RCT comparing cabergoline and pyridoxine for lactation inhibition in postpartum patients. Cabergoline was more effective than pyridoxine at day 7, but pyridoxine had fewer adverse effects. Pyridoxine inhibited lactation successfully in 67% of patients, suggesting it as an alternative for those with contraindications to cabergoline.
Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.
Randomized trial assessing pyridoxine's effectiveness in preventing hand-foot syndrome (HFS) induced by pegylated liposomal doxorubicin in multiple myeloma patients. Pyridoxine reduced the incidence of HFS compared to no pyridoxine, with 5.8% vs 20.8% experiencing HFS, respectively.
Pyridoxine for treatment of levetiracetam-induced behavioral adverse events: A randomized double-blind placebo-controlled trial.
This randomized double-blind placebo-controlled trial investigated the effect of 40 mg/day pyridoxine on behavioral side effects of levetiracetam in 53 adult epilepsy patients. The study found no statistically significant differences in behavioral adverse effects between the pyridoxine and placebo groups.
Amelioration of Levetiracetam-Induced Behavioral Side Effects by Pyridoxine. A Randomized Double Blind Controlled Study.
RCT in a pediatric tertiary hospital assessing pyridoxine supplementation to mitigate neuropsychiatric side effects of levetiracetam in 105 children with epilepsy. The study found that therapeutic doses of pyridoxine led to a more prominent improvement in behavioral symptoms compared to placebo.
Randomized trial of high-dose pyridoxine in combination with standard hormonal therapy in West syndrome.
Open-label RCT comparing high-dose oral pyridoxine in combination with standard ACTH therapy to ACTH therapy alone in children with West syndrome. The study found no evidence of superiority for pyridoxine in cessation of epileptic spasms, with comparable adverse events in both groups.
A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Pilot randomized double-blind, placebo-controlled study on the effects of topical pyridoxine on palmar-plantar erythrodysesthesia (PPE) in patients treated with capecitabine or pegylated liposomal doxorubicin. No significant effect on PPE grade was found, but pyridoxine improved quality of life, pain levels, and various health status measures.
Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Meta-analysis assessing prevention and treatment strategies for capecitabine-induced hand-foot syndrome. Celecoxib was associated with a lower incidence of grade ≥2 HFS, while pyridoxine and topical urea/lactic acid were not effective in preventing or treating HFS.
8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information.
Unpublished 1970s RCT evaluating doxylamine, pyridoxine, and dicyclomine for nausea and vomiting during pregnancy. The study found higher efficacy in active treatment groups compared to placebo, but results are unreliable due to high attrition and data integrity issues.
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
This randomized, double-blind, placebo-controlled phase 3 trial assessed whether oral pyridoxine could prevent the onset of grade 2 or higher hand-foot syndrome (HFS) in 210 patients receiving capecitabine chemotherapy. Pyridoxine did not significantly prevent or delay the onset of grade 2 or higher HFS. Serum and red blood cell folate levels were independent predictors of HFS.
Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency.
Systematic review providing guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. Recommendations include treatment with a low-methionine diet, betaine, and pyridoxine, with a focus on maintaining plasma homocysteine levels below 100 μmol/L to prevent complications.
Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial.
RCT evaluating the maternal safety of the delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Diclegis) in pregnant women with nausea and vomiting. The study found no increased rate of adverse events compared to placebo, indicating the combination is safe and well tolerated.
How to manage neonatal tuberculosis.
The article provides recommendations for managing neonatal tuberculosis, emphasizing the importance of prompt investigation and treatment. It suggests that breast-fed newborns treated with isoniazid should receive pyridoxine supplementation to prevent deficiency.
Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess.
Systematic review of literature on neuropathy attributed to pyridoxine deficiency and excess. Concludes that very low doses of pyridoxine are needed to prevent neuropathy, but doses greater than 50 mg/d may be harmful.
Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis.
Meta-analysis assessing the efficacy of pyridoxine supplements in managing hand-foot syndrome (HFS) during chemotherapy. The analysis included eight studies for preventive efficacy and three for treatment efficacy. Pyridoxine showed significant efficacy in treating HFS but not in preventing it.
Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.
Systematic review and meta-analysis of prevention strategies for chemotherapy-induced hand-foot syndrome (HFS). Celecoxib showed efficacy in preventing moderate to severe and all-grade HFS, while pyridoxine and topical urea/lactic acid formulations did not prove effective.
Carpal tunnel syndrome.
Systematic review evaluating the effectiveness and safety of various interventions for carpal tunnel syndrome, including acupuncture, diuretics, carpal tunnel release surgery, corticosteroids, massage therapy, nerve and tendon gliding exercises, NSAIDs, pyridoxine, therapeutic ultrasound, and wrist splints.
Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis.
Re-analysis of a randomized controlled trial comparing doxylamine-pyridoxine to placebo for nausea and vomiting during pregnancy. The study found a trend towards efficacy with doxylamine-pyridoxine, but statistical significance depended on the method of handling missing data, and the difference was not clinically important.
Comparing the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in nonpregnant women of reproductive age and women in the first trimester of pregnancy.
The study compared the pharmacokinetics of doxylamine/pyridoxine delayed-release combination in 18 nonpregnant women and 50 pregnant women in their first trimester. No significant differences were found in the apparent clearance of doxylamine or pyridoxal 5'-phosphate between the two groups.
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
RCT comparing 200 mg versus 400 mg daily of pyridoxine in preventing palmar-plantar erythrodysesthesia (PPE) in capecitabine-treated cancer patients. The high dose arm had less PPE and a longer time to development of grade 2 or greater PPE compared to the low dose arm. However, the 400 mg pyridoxine group had a worsened tumor response and tended to have greater tumor treatment failure.
Carpal tunnel syndrome.
Systematic review evaluating the effectiveness and safety of various interventions for carpal tunnel syndrome, including acupuncture, surgery, diuretics, corticosteroids, massage therapy, NSAIDs, pyridoxine, therapeutic ultrasound, and wrist splints.
Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis.
Double-blinded, placebo-controlled study on pyridoxine supplementation in rheumatoid arthritis patients with subnormal vitamin B6 status. Supplementation improved vitamin B6 status but did not affect pro-inflammatory cytokine production.
Conservative treatment options for carpal tunnel syndrome: a systematic review of randomised controlled trials.
Systematic review of randomized controlled trials evaluating conservative treatment options for carpal tunnel syndrome (CTS). Diuretics, pyridoxine, NSAIDs, yoga, and laser-acupuncture were found ineffective for short-term symptom relief, while steroid injections showed limited effectiveness. Conflicting evidence exists for ultrasound and oral steroids, with limited evidence supporting ultrasound for long-term relief.
Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial.
RCT of 342 pregnant women at ≤17 weeks' gestation comparing 30 mg/day oral pyridoxine hydrochloride to placebo for nausea and vomiting. Pyridoxine significantly decreased nausea severity compared to placebo, though reduction in vomiting episodes was not statistically significant.
Comparing pyridoxine and doxylamine succinate-pyridoxine HCl for nausea and vomiting of pregnancy: A matched, controlled cohort study.
Matched, controlled cohort study comparing pyridoxine (vitamin B6) and doxylamine succinate-pyridoxine HCl for nausea and vomiting of pregnancy (NVP). Doxylamine succinate-pyridoxine HCl showed a significant reduction in PUQE scores compared to pyridoxine, especially in women with severe symptoms.
Pyridoxine supplementation does not alter in vivo kinetics of one-carbon metabolism but modifies patterns of one-carbon and tryptophan metabolites in vitamin B-6-insufficient oral contraceptive users.
RCT investigating the effects of vitamin B-6 supplementation on one-carbon metabolism and tryptophan metabolites in vitamin B-6-deficient oral contraceptive users. Pyridoxine supplementation increased plasma PLP concentration but did not affect in vivo rates of homocysteine remethylation. Metabolite profiles showed changes, indicating functional vitamin B-6 deficiency.
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
RCT comparing ondansetron to pyridoxine and doxylamine for treating nausea and vomiting in pregnancy. Ondansetron showed greater improvement in nausea and vomiting over 5 days compared to pyridoxine and doxylamine.
Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin.
RCT administering folic acid, pyridoxine, and cyanocobalamin to 21 dialysis patients for 4 weeks. The study found a significant reduction in homocysteine, fibrinogen, and lipoprotein(a) levels, suggesting a favorable effect on atherosclerosis risk factors in patients with renal failure.
A meta-analytic review of the preventive treatment of recurrences of febrile seizures.
Meta-analysis of randomized, placebo-controlled trials assessing the efficacy of various medications, including pyridoxine, in preventing recurrent febrile seizures. Pyridoxine did not show a significant difference in risk of recurrences compared to placebo.
Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies.
Meta-analysis of 16 cohort and 11 case-control studies assessing birth defects from Bendectin-exposed pregnancies. The pooled estimate of relative risk for malformations at birth associated with Bendectin exposure was 0.95, indicating no significant difference in risk of birth defects between exposed and non-exposed groups.
Vitamin B-6 status of breast-fed neonates: influence of pyridoxine supplementation on mothers and neonates.
Mothers were supplemented with 2 or 27 mg pyridoxine-HCl/d during the first 28 days of lactation, and a subgroup of infants received 0.4 mg PN-HCl/d. Vitamin B-6 intake of mothers strongly influenced infant vitamin B-6 status, with higher intakes correlating with better vitamin B-6 status in infants. Plasma PLP concentrations and birth weight were strong predictors of infant growth.
Effect of maternal pyridoxine X HCl supplementation on the vitamin B-6 status of mother and infant and on pregnancy outcome.
The study investigated the effect of maternal pyridoxine HCl supplementation on vitamin B-6 status and pregnancy outcomes. It found that supplementation with 7.5 mg or more of PN-HCl was necessary to maintain maternal plasma PLP levels and improve Apgar scores at birth.
Response of vitamin B-6 deficiency and the carpal tunnel syndrome to pyridoxine.
The study investigated the effect of pyridoxine (vitamin B-6) supplementation on carpal tunnel syndrome (CTS) patients with a deficiency in vitamin B-6. A double-blind treatment showed that pyridoxine improved clinical symptoms of CTS, correlating with restored levels of the transaminase enzyme.
The use of nicotinic acid and pyridoxine in the treatment of schizophrenia.
RCT testing the hypothesis that combined administration of nicotinic acid and pyridoxine has greater therapeutic effects than the component drugs in chronic schizophrenic patients. The study found that supplementation with a single vitamin produced significant therapeutic changes, while supplementation with both did not.
High-dose pyridoxine treatment for inherited glycosylphosphatidylinositol deficiency.
Prospective open-label multicenter pilot study assessing high-dose pyridoxine treatment for seizures and development in patients with inherited glycosylphosphatidylinositol deficiencies. Seizure frequencies were significantly reduced in some patients, and modest developmental improvements were observed. Treatment was generally safe with mild transient diarrhea in one patient.
Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.
The study examined the effect of the COMT(L) allele on the clinical response to high dose pyridoxine in Parkinson's disease patients. Patients on stable levodopa doses showed improved motor and activities of living scores after pyridoxine, with the best outcomes in COMT(L/L) homozygotes. The study suggests the COMT(L) variant may help select PD patients for pyridoxine therapy.
High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study.
A 10-week double-blind, placebo-controlled trial with 10 children with autism examined the efficacy and safety of high-dose pyridoxine and magnesium. The study found that the intervention was ineffective in ameliorating autistic behaviors, with no clinically significant side effects noted.
Pyridoxine in atopic dermatitis.
RCT of 48 children with moderate or severe atopic dermatitis comparing pyridoxine hydrochloride 50 mg daily to placebo for 4 weeks. No statistically significant difference in clinical severity scores or symptom scores was found between the groups.
Vitamin B-6 requirement and status assessment: young women fed a depletion diet followed by a plant- or animal-protein diet with graded amounts of vitamin B-6.
This study assessed the vitamin B-6 requirement in young women consuming a high-protein diet and the effect of protein quality on this requirement. Eight women were fed a depletion diet followed by either an animal-protein or plant-protein diet with graded vitamin B-6 intakes. Results indicated that a plant-protein diet does not increase the vitamin B-6 requirement compared to an animal-protein diet, and specific intake levels normalized most biochemical indexes of vitamin B-6 status.
Pyridoxine supplementation: effect on lymphocyte responses in elderly persons.
RCT investigating the effect of pyridoxine supplementation on lymphocyte responsiveness in 15 elderly persons. Pyridoxine supplementation increased plasma PLP levels and significantly enhanced lymphocyte proliferation and T cell subpopulations, suggesting improved immunocompetence.
Clinical trial of pyridoxine to reduce vincristine neurotoxicity.
RCT evaluating pyridoxine's protective effects against vincristine-induced neurotoxicity in breast cancer patients. Pyridoxine did not reduce neurotoxic side effects compared to the control group.
Effect of pyridoxine on plasma levels of HGH, PRL, and TSH in normal women.
The study investigated the effect of chronic administration of pyridoxine (vitamin B6) on HGH, basal and TRH stimulated PRL and TSH levels in seven healthy female volunteers. HGH and TSH basal levels remained unaffected, while basal PRL and TRH stimulated PRL and TSH levels were slightly reduced without statistical significance.
Pyridoxamine Supplementation Effectively Reverses the Abnormal Phenotypes of Zebrafish Larvae With PNPO Deficiency
The study used zebrafish with reduced Pnpo activity as a model for PNPO-deficiency NEE. Pyridoxamine supplementation effectively reversed developmental anomalies, including brain malformation and impaired locomotor activity, suggesting a potential new therapeutic treatment for PNPO-deficiency NEE.
Pyridoxine-responsive gyrate atrophy of the choroid and retina: clinical and biochemical correlates of the mutation A226V.
The study identified the A226V mutation in the OAT genes of patients with gyrate atrophy of the choroid and retina. Pyridoxine supplementation significantly decreased plasma ornithine levels in one patient, and increased OAT activity in fibroblasts and cells expressing the mutation.
Adequacy of vitamin B6 supplementation during pregnancy: a prospective study.
Prospective study assessing the effect of 2.5, 4, and 10 mg of pyridoxine supplementation during pregnancy on maternal and fetal plasma levels of pyridoxal 5'-phosphate (PLP) and enzyme saturation in maternal erythrocytes. More than 4 mg of pyridoxine was required to maintain adequate maternal plasma PLP levels, indicating that the current RDA for vitamin B6 during pregnancy is too low.
Effect of pyridoxine deficiency and prednisolone on beta-alanine-oxoglutarate aminotransferase and D-3-aminoisobutyrate aminotransferase in rat liver and kidney.
The study investigates the effect of pyridoxine deficiency and prednisolone on beta-alanine-oxoglutarate aminotransferase and D-3-aminoisobutyrate aminotransferase activities in rat liver and kidney. Pyridoxine deficiency suppressed enzyme activities in the kidney but not in the liver, while prednisolone induced beta-Ala-T I in the liver but had no effect on beta-Ala-T II.
New developments in pediatric psychopharmacology.
Report on recent developments in pediatric psychopharmacology, reviewing drugs including tryptophan and pyridoxine for indications such as prepubertal depression and learning disabilities. Information is preliminary and caution is advised.